Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00598793 · ClinicalTrials.gov registry record · Phase 3
Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy
A Phase 3 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 242
- Enrollment target
NCT00598793: Completed Phase 3 study, sponsored by Novo Nordisk A/S.
NCT00598793 is a Phase 3 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 242 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00598793, a Phase 3 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 242 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insulin naive and failing OAD therapy.
Interventions
- DRUG metformin
- DRUG biphasic insulin aspart
- DRUG insulin glargine
- DRUG pioglitazone
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 242 participants |
| Start Date | 2002-11 |
| Est. Completion | 2004-03 |
| Phase | Phase 3 |
What the finished NCT00598793 record still lists
NCT00598793 is an interventional study that assigns participants to a tested intervention. The registered 242 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (69% lower).
The record links to 0 conditions, and to 4 interventions - of which metformin is the first listed.
NCT00598793 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00598793 about?
NCT00598793 is a clinical study titled "Biphasic Insulin Aspart 30 in Type 2 Diabetes Failing OAD Therapy". This trial is conducted in the United States of America (USA). The aim of this trial is to compare biphasic insulin aspart 30 plus metformin in a standard injection regimen to a standard dosing of insulin glargine plus metformin on blood glucose control in subjects with type 2 diabetes who are insul...
What is the current status of trial NCT00598793?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 242 participants. The study started on 2002-11. Estimated completion is 2004-03.
What interventions are being tested in trial NCT00598793?
The interventions under investigation include: metformin (DRUG), biphasic insulin aspart (DRUG), insulin glargine (DRUG), pioglitazone (DRUG).
Who is sponsoring clinical trial NCT00598793?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00598793's enrollment target sits among peer trials
242 1270th of 2000 higher than 729 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03556228 · 242 participants · Phase 1
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- NCT04260022 · 242 participants · Phase 1
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
- NCT04459000 · 242 participants · NA
Substance Use Treatment and Access to Resources (STARS) Project
- NCT05644496 · 242 participants · Phase 4
ZYNRELEF for Pain Management in Total Knee Arthroplasty
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia